Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

The Eli Lilly & Co. logo at the company's Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024.Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations.The drugmaker's shares dropped about 6% in early trading Tuesday.Eli Lilly said it now expects full-year 2024 revenue of about $45 billion. That's lower than the $45.4 billion to $46 billion the company anticipated in October. The new outlook would ...